FindTrial
Sign In

A single-center, prospective, open-label study investigating the effect of Ninjin'yoeito on frailty in hemodialysis patients.

A single-center, prospective, open-label study investigating the effect of Ninjin'yoeito on frailty in hemodialysis patients. - Effects of Ninjin'yoeito on frailty in hemodialysis patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052058
Enrollment
40
Registered
2023-08-31
Start date
2023-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frailty in hemodialysis patients

Interventions

Kracie Ninjin&#39
yoeito, 7.5g per day, 1year No Kracie Ninjin&#39
yoeito medication

Sponsors

Japanese Red Cross Kumamoto Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients who have been on hemodialysis at our outpatient department for more than 3 months at the start of the study. 2.Patients who have provided consent for participation.

Exclusion criteria

Exclusion criteria: 1. Patients who have difficulty obtaining consent due to dementia 2. Patients with terminal cancer, with acute cardiovascular disease, before and after surgery, and with serious trauma.

Design outcomes

Primary

MeasureTime frame
Blood collection data, muscle mass, physical function, weight, and Quality of Life at the start of oral use and one year after—

Countries

Japan

Contacts

Public ContactChiaki Kawabata

Japanese Red Cross Kumamoto Hospital Department of Nephrology

chiaki-kawabata@hotmail.co.jp096-384-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026